CLL-1 is expressed in 92% of primary AML samples[50] and expressed on LSCs in the majority of AML patients, but it is absent on HSCs from healthy and regenerating BM from patients who received chemotherapeutic treatment[51,52]. Here, CLEC12A is linked to acute myeloid leukemia.